Moxifloxacin-Associated Drug Hypersensitivity Syndrome With Toxic Epidermal Necrolysis and Fulminant Hepatic Failure
Geneesmiddel: moxifloxacin
Auteurs: Sarita Nori; Chris Nebesio; Ryan Brashear; Jeffrey B. Travers
Publicatie: Archives of Dermatology
Publicatiedatum: Arch Dermatol. 2004;140:1537-1538.
Extra info: Moxifloxacin is a newer-generation fluoroquinolone antibiotic that is Food and Drug Administration–approved for the treatment of acute bacterial sinusitis, bronchitis, community-acquired pneumonia, and skin infections.1 It has broad-spectrum activity against gram-positive and gram-negative organisms.1 We report the first case of moxifloxacin-associated drug-hypersensitivity syndrome associated with toxic epidermal necrolysis (TEN) and fulminant fatal hepatic failure.

Report of a Case

A 23-year-old woman, previously healthy and with no known drug allergies or prior treatment with fluoroquinolones, was given moxifloxacin (Avelox; Bayer Corp, West Haven, Conn) for an upper respiratory illness. After 3 days she developed nausea, vomiting, and abdominal pain, and a morbilliform eruption that localized to her abdomen; at this point moxifloxacin treatment was stopped. At a local emergency department she was found to have increased liver enzyme levels, fever, and lymphadenopathy. She had long been taking oral contraceptives, but she denied using other medications or supplements or having recently traveled. Blood tests . . .

archderm.ama-assn.org/cgi/content/extract/140/12/1537 - 28 dec 2004